国家医保局：严肃核查处置定点药店“阴阳价格”问题

Core Viewpoint - The National Healthcare Security Administration has issued a notice to strengthen monitoring and handling of "dual pricing" practices in designated retail pharmacies, where the same medication is sold at higher prices to insured patients compared to uninsured patients, which is considered price fraud and a violation of service agreements [1][2][4]. Group 1: Monitoring and Reporting - Local healthcare departments are urged to recognize the infringement of insured patients' rights due to "dual pricing" practices and the negative impact on healthcare funds [2][3]. - There is a call for proactive screening of key drug varieties, focusing on those with significant price discrepancies or high settlement amounts, utilizing data from insurance settlements and public feedback [3][4]. - The involvement of social supervision is encouraged, allowing the public to report "dual pricing" practices and potentially receive rewards for providing relevant information [3]. Group 2: Investigation and Enforcement - Local healthcare departments must fulfill their responsibilities by collaborating with market regulation authorities to conduct thorough investigations and checks on pharmacies suspected of "dual pricing" [4]. - Data screening and on-site inspections are to be enhanced, focusing on pharmacies with reported pricing anomalies and ensuring compliance with service agreements [4][5]. - Serious violations may lead to penalties, including suspension of insurance settlements and termination of service agreements, to protect healthcare funds and patient rights [4][5]. Group 3: Ongoing Monitoring and Management - Continuous management of drug pricing in designated pharmacies is emphasized, with a focus on maintaining fair pricing practices [5][6]. - The use of a drug price comparison app is encouraged to facilitate transparency and allow patients to compare prices among pharmacies [6]. - Regular monitoring of high-risk drug pricing and ensuring accurate data submission by pharmacies are critical to prevent discriminatory pricing practices [6][7].